Associated tags: Endoscopy, Medtronic, Mesalazine, Intelligence, Cancer, Rifamycin, GI, Satellite navigation device, C43, Pharmaceutical industry, XETRA, Patient, Acne, Sun Pharma
Locations: CHINA, PAKISTAN, BANGLADESH, TAIWAN, HONG KONG, EASTERN, BHUTAN, NEPAL, IRAN, APAC, LATIN AMERICA, EUROPE, YEMEN, OMAN, ALGERIA, IRAQ, TUNISIA, SYRIA, JORDAN, SAUDI ARABIA, LEBANON, UAE, QATAR, EGYPT, LIBYA, MOROCCO, MIDDLE EAST, SUDAN, BAHRAIN, MENA, KUWAIT, UNITED ARAB EMIRATES, IRLAND, EUROPEAN UNION, US, IRELAND, COSMO, EU
Retrieved on:
Monday, December 11, 2023
NYSE,
Medtronic,
Patient,
Fruit,
FDA,
GI,
Caregiver,
Partnership,
Health,
AI,
Gastroenterology,
Adenoma,
Endoscopy,
Medical device,
Pharmaceutical industry DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable healthcare advancements for patients and caregivers globally. Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes. This strategic alliance reinforces Medtronic's position in AI-integrated healthcare solutions and represents a significant leap in incorporating AI into endoscopic care.
Key Points:
- Agreement expands partnership between Medtronic and Cosmo Pharmaceuticals, set to transform endoscopy with cutting-edge AI technology
DUBLIN, Dec. 11, 2023 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its partnership with Cosmo Intelligent Medical Devices, a subsidiary of Cosmo Pharmaceuticals.
- Through this exclusive global partnership, Medtronic and Cosmo Pharmaceuticals remain committed to revolutionizing endoscopy by harnessing the power of AI to improve patient outcomes.
- "Our expanded partnership with Cosmo Pharmaceuticals is a strategic milestone in our mission to leverage AI for enhanced patient care," said Geoff Martha, chairman and chief executive officer at Medtronic.
- Cosmo Pharmaceuticals will continue to be the exclusive manufacturer, granting Medtronic exclusive, global, commercial rights.
Retrieved on:
Thursday, December 14, 2023
Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash.
Key Points:
Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Unsecured Convertible Bonds due 2023 in cash.
Retrieved on:
Tuesday, October 17, 2023
III,
European,
Prescription,
IQVIA,
Cosmo,
Ageing,
Safety,
Sun Pharma,
EMA,
FDA,
Marketing Authorisation Application,
European Medicines Agency,
Marketing,
IGA,
Acne,
XETRA,
Dermatology,
Patient,
C43,
MAA,
Pharmaceutical industry,
Medical device,
EU This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
Key Points:
- This filing marks a significant milestone in pipeline progression, as approval will open the substantial EU market to already selected, high-standing partners.
- Cosmo has officially submitted the Marketing Authorisation Application (MAA) for its innovative acne treatment clascoterone 1% cream (Winlevi®) to the European Medicine Agency (EMA) through the centralized procedure, aimed at obtaining a single Marketing Authorization for the product in the European Union.
- The EMA's rigorous evaluation process will assess the product's safety, quality, and efficacy, ultimately determining its suitability for approval within the European market.
- This submission to the EMA is a pivotal step forward in our mission as well as a testament to our ongoing commitment to innovation.
LSE,
IQVIA,
African,
XETRA,
Clascoterone,
Acne,
Sun Pharma,
Prescription,
USD,
Dermatology,
C43,
Patient,
OTC,
Ageing,
Kingdom,
FDA,
Nasdaq Dubai,
Health,
Skin,
Pharmaceutical industry,
Cassiopea Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.
Key Points:
- Under the terms of the agreement, Hikma will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in 17 Middle Eastern and North African countries.
- Cassiopea will receive an upfront payment of USD 750,000 in addition to potential regulatory and sales milestones.
- Cassiopea will be the exclusive supplier of the product at a price calculated on the net sales.
- Over 15,000 US health care providers have prescribed Winlevi® to date which represents 88% of total health care providers in dermatology.
Retrieved on:
Monday, September 4, 2023
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Key Points:
- Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license with Dr. Falk Pharma for Rifamycin SV MMX® in the EU and other selective countries.
- Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers' Diarrhea caused by certain bacteria.
- It is the first antibiotic engineered with Cosmo’s proprietary Multi Matrix Technology (MMX®).
- MMX technology is designed to deliver the active pharmaceutical ingredients in a delayed and controlled manner directly to the lower intestine.
Retrieved on:
Monday, September 4, 2023
Partnership,
Diarrhea,
XETRA,
Traveler,
C43,
Patient,
MMX,
Growth,
Bacteria,
MENA,
Airline,
Pharmaceutical industry,
EU,
LATAM Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Key Points:
- Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd. (“Adalvo”) today announced the signing of a license and supply agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions.
- Under the terms of the agreement, Adalvo will receive from Cosmo the exclusive right to develop, register and commercialize Rifamycin SV MMX® 200mg in these respective regions.
- Cosmo will receive an upfront payment in addition to potential regulatory and sales milestones and customary double-digit royalties on net sales.
- Rifamycin SV MMX® is an orally administered, delayed-release, non-systemic antibiotic approved for the treatment of Travelers' Diarrhea caused by certain bacteria.
Please note that there is a function to type in your questions via webcast.
Key Points:
- Please note that there is a function to type in your questions via webcast.
- Participants wishing to ask verbal questions via phone, may call the following numbers below.
- To ensure prompt access, please call approximately ten minutes prior to the scheduled start of the call.
- The webcast, along with the presentation, will be available online shortly after the event and accessible for three months.
AGA is the most common form of hair loss and a substantial market with high unmet needs. It is an extremely common disorder that affects roughly 50% of men
Key Points:
AGA is the most common form of hair loss and a substantial market with high unmet needs. It is an extremely common disorder that affects roughly 50% of men
Budesonide,
Ferring Pharmaceuticals,
Bleeding,
Prevalence,
IBD,
Medicines and Healthcare products Regulatory Agency,
Bausch,
Weight loss,
Quality of life,
XETRA,
Cramp,
Inflammation,
Diarrhea,
Colon,
Tablet,
Inflammatory bowel disease,
Defecation,
C43,
UC,
Cosmo,
Ulcerative colitis,
PMDA,
MMX,
Bloating,
Ulcer,
Fatigue,
Pharmaceutical industry Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Key Points:
- Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the approval for Cortiment® (budesonide 9 mg MMX tablets) in Japan by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
- First sales of Cortiment® in Japan are expected to begin by end of Q3 2023.
- Cortiment® has been developed by Cosmo and is globally distributed by Ferring, with the exception of the US, where it is distributed by Bausch.
- Alessandro Della Chà, CEO of Cosmo Pharmaceuticals, comments: “We are very pleased with the new success our partner Ferring Pharmaceuticals has achieved with Cortiment®.
National health insurance,
Male,
Partnership,
Androgen,
IQVIA,
Pharming,
Quality of life,
XETRA,
Clascoterone,
Hira,
Sun Pharma,
Acne,
Prescription,
Incidence,
Spironolactone,
C43,
Hyundai,
Patient,
Physician,
South Korea,
Health Insurance Review and Assessment Service,
License,
Ageing,
FDA,
Skin,
HIRA,
Female,
Pharmaceutical industry,
Cassiopea Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.
Key Points:
- Dublin, Ireland & Seoul, Korea – 22 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hyundai Pharmaceutical Co., Ltd. (“Hyundai Pharm”) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in the Republic of Korea.
- Under the terms of the agreement, Hyundai Pharm will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to register and commercialize Winlevi® in the Republic of Korea.
- With this license agreement, Hyundai Pharm aims to address this unmet medical need by offering a new treatment option for both male and female acne patients in South Korea.
- SangJoon Lee, Chief Executive Officer of Hyundai Pharm, said “We are delighted to establish a strategic partnership through the licensing agreement with Cosmo and its subsidiary, Cassiopea.
